? Abramson Cancer Center BioRepository (ABR) The Abramson Cancer Center BioRepository (ABR) is a shared core laboratory comprised of four integrated components that together enable the collection of tumor and normal tissue samples from surgical resections and radiology guided biopsy (supporting clinical trials), blood collections (buffy coats, serum and plasma), and liquid biopsy (ctDNA, CTC, soluble proteins and extra-cellular vesicles). This integrated Shared Resource leverages uniformity of quality across a breadth of biosamples and enhanced efficiencies gained through use of a universal consent. The tumor tissue, blood collection and liquid biopsy material collections are supported by a new prospective universal consent allowing for collection of blood and tissue (at time of surgery), patient re-contact, ?omics? study of the collected biosamples, and linkage to electronic health records for outcome- related translational research. Biosample inventory data are managed through Open Specimen, a commercial biosample database on the tissue side, and Pumpkin, a home-grown system for blood sample processing ? both well-suited to handle large volume sample collections and archiving. Penn Medicine has a centralized informatics infrastructure (PennOmics v2) composed of an enterprise DataLake that combines EHR data, tumor registry data, and genomic data (germline and somatic studies) that links to stored biosample inventories across our biosample database (Open Specimen and Pumpkin) that allows for cohort exploration and requesting biosamples from these cohorts. Biosamples are stored in two new freezer farms recently constructed at the Perelman School of Medicine in either -80 freezers (buffy coats, plasma and serum) or LN2 vapor (tissue or viable cells). Both freezer farms have completely redundant air conditioning, electric and central monitoring resources including remote monitoring and alarms with O2 security sensors to support LN2 vapor storage. ABR is tightly coupled with a larger institutional biosample repository (Penn Medicine Biobank) which has grown to >60K patient blood samples, including whole exome sequencing and genotyping on >15K of these patients. The Penn Medicine Biobank is a broad effort across Penn Medicine that seeks to collect blood and tissues across a wide range of both normal patients as well as patients with a variety of diseases. The ABR Shared Resource is directed by Dr. Michael Feldman, who has been leading the tumor tissue and blood repository since its inception in 2005. Ms. Joellen Weaver, Technical Director, has worked in biobanking for 20 years. ACC members accounted for 43 of 62 investigators (69%) using this Shared Resource during the most recent reporting period (07/01/18-06/30/19). ABR has supported high-impact research, e.g. changing the fundamental understanding of immune suppression in tumors via PDL1-carrying exosomes (Chen et al., Nature, 2018). ABR facilitates access to a wide variety and number of biospecimens for ACC members across the basic, clinical, and population science Programs, addressing the changing scientific needs of ACC membership and increased research demand for tissue and blood products.
Showing the most recent 10 out of 1047 publications
